Developing a Predictive Biomarker as a Companion Diagnostic for a Molecularly Targeted Cancer Drug. Richard Simon, D.Sc. Chief, Biometric Research Branch National Cancer Institute http://brb.nci.nih.gov. BRB Website http://brb.nci.nih.gov. Powerpoint presentations Reprints
Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.
Richard Simon, D.Sc.
Chief, Biometric Research Branch
National Cancer Institute
How Can We Develop New Drugs in a Manner More Consistent With Modern Tumor Biology and ObtainReliable Information About What Regimens Work for What Kinds of Patients?
Develop Predictor of Response to New Drug Diagnostics
Using phase II data, develop predictor of response to new drug
Patient Predicted Responsive
Patient Predicted Non-Responsive
Develop anti-EGFR antibodies in colorectal cancer and would not have been successful Predictor of
Response to New Rx
To New Rx
Predicted Non-responsive to New Rx
Use of Archived Specimens in Evaluation of Prognostic and Predictive BiomarkersRichard M. Simon, Soonmyung Paik and Daniel F. HayesJNCI (In Press)
Use of Archived Specimens in Evaluation of Prognostic and Predictive BiomarkersRichard M. Simon, Soonmyung Paik and Daniel F. Hayes JNCI (In Press)